Expression of miR-630 associated with tyrosine kinase inhibitor therapeutic response in lung adenocarcinoma cases

The published manuscript entitled “A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop” by Wu et al., may be beneficial for all clinicians treating lung adenocarcinomas (1) . There is paucity of reports on the role of miR-630 expression in lung cancers.